Key takeaways
- We found no UK legislation that names MOTS-c, and the emc, the UK database of licensed medicines’ product information, returned no product containing it (18 Nov 2026).
- Selling or supplying an unauthorised medicinal product is an offence under the Human Medicines Regulations 2012, with a maximum of two years’ imprisonment, a fine or both on indictment.
- The MHRA classifies finished products, not substances, and told STV News in March 2026 that it disregards “research purposes” claims used to avoid medicines law.
- MOTS-c is not listed in Schedule 2 to the Misuse of Drugs Act 1971; whether a product is a medicine is a separate question.
- In UK sport, WADA names MOTS-c in class S4.4.1, prohibited at all times; UK Anti-Doping called the 2025 List’s new examples “additional examples of substances that are already prohibited”.
01What does UK law say about MOTS-c?
UK medicines law keeps no list of peptides. It asks what a product is, and then who may sell, supply or advertise it. We found no UK legislation that names MOTS-c.
Is the product a medicine? Regulation 2 of the Human Medicines Regulations 2012 has two limbs. A product is a medicinal product if it is “presented as having properties of preventing or treating disease in human beings”. It is also one if it “may be used by or administered to human beings” to restore, correct or modify a physiological function “by exerting a pharmacological, immunological or metabolic action”. Either limb is enough.
What follows if it is. Regulation 46(1) says: “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.” Regulation 46(4) and (5) also bar manufacturing or assembling one, or procuring its sale, supply, manufacture or assembly, where the person knows or has reasonable cause to believe it is to be sold or supplied in breach of 46(1). Regulation 47 makes a breach an offence, punishable on indictment by “a fine, to imprisonment not exceeding two years or to both”.
Advertising. Regulation 279 says a person “may not publish an advertisement in Great Britain for a medicinal product” unless a UK marketing authorisation, a temporary authorisation, a certificate of registration or a traditional herbal registration is in force for it. Regulation 303 makes a breach an offence, with the same two-year maximum on indictment.
The narrow exception. Regulation 167 covers “specials”: products made to a prescriber’s specification, in response to an unsolicited order, for the special needs of a patient that prescriber is directly responsible for, and never advertised. It serves one patient at a time; it is not a route to a market.
| Provision | What it covers | Maximum on indictment |
|---|---|---|
| Human Medicines Regulations 2012, reg 2 | Defines a medicinal product, by presentation or by function | Definition only |
| Reg 46(1) | Selling or supplying, or offering to, an unauthorised medicinal product | 2 years, a fine or both (reg 47) |
| Reg 46(4) and (5) | Manufacturing, assembling or procuring the sale of one meant for sale in breach of 46(1) | 2 years, a fine or both (reg 47) |
| Reg 279 | Advertising a medicinal product with no UK authorisation in force | 2 years, a fine or both (reg 303) |
| Reg 167 | Specials for an individual patient, made to a prescriber’s specification, unadvertised | An exception, not an offence |
| Misuse of Drugs Act 1971, Sch 2 | Controlled drugs, Classes A to C | MOTS-c is not listed |
02How would the MHRA decide whether a MOTS-c product is a medicine?
Product by product. The MHRA’s Guidance Note 8 says: “The MHRA only classifies finished products and not individual substances and ingredients.”
The guidance lists what the MHRA weighs. Among the factors are the ingredients’ pharmacological, immunological or metabolic properties, the product form (“capsule, tablet, injection, etc.”) and the way it is to be used, the product literature, and “the risks which use of the product may pose.” Among the kinds of marketing that it says may suggest a medicine are “references to medical conditions” and “references to medical and / or clinical research and testing”.
For the function limb, the guidance quotes the European Court of Justice: the authorities “must decide on a case-by-case basis, taking account of all the characteristics of the product, in particular its composition, its pharmacological, immunological or metabolic properties”. The MHRA’s borderline-products guidance, updated on 2 July 2026, adds how a product “is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews”.
Research labels. In a statement to STV News in March 2026, the MHRA’s head of borderlines said the agency disregards “research purposes” claims “if it is clear that such claims are being used as an attempt to avoid medicines regulations.” The statement went on: “If a product is classified as a medicine and is not appropriately authorised, we take regulatory compliance action, including the removal of the product from the UK market where necessary.” It did not name MOTS-c. More on labels: what “research use only” means.
Is any MOTS-c product licensed? We found none. On 18 November 2026 the emc, the UK database of licensed medicines’ product information, returned “No search results” for “MOTS-c”, “MOTS c” and “mitochondrial open reading frame”; the same search for somatropin returned 21. The European Medicines Agency’s medicines data export of the same day has no MOTS-c entry. In a 2026 briefing, FDA staff also reported that the EMA “did not list any products containing MOTS-c or MOTS-c acetate that are authorized for use.” We could not run the MHRA Products search, which needs a browser.
03What have UK authorities done, and when?
A dated record, from the sports listing to the 2026 enforcement wave. None of the MHRA documents below names MOTS-c. Press reports are marked.
| Date | Who | What happened |
|---|---|---|
| 25 Sep 2024 | WADA | Publishes the 2025 Prohibited List, which adds MOTS-c by name as an example in class S4.4.1; UK Anti-Doping called that year’s new examples substances “already prohibited” |
| 1 Jan 2025 | WADA | The 2025 List takes effect, in UK sport as everywhere the Code applies |
| 25 Feb 2026 | MHRA Criminal Enforcement Unit | Announces raids on a farm near Sleaford and a residential address in Grantham, believed to be used to make and distribute unlicensed weight-loss medicines “as well as peptide products” |
| 19 Mar 2026 | MHRA, statement to STV News (press report) | Says it disregards “research purposes” claims used to avoid medicines regulations |
| 12 May 2026 | MHRA | Replaces Guidance Note 8 with an amended version |
| 28 May 2026 | MHRA Criminal Enforcement Unit | Raids an estate near Northampton believed to make and distribute unlicensed weight-loss medicines “as well as peptide products”; two arrests |
| 2 Jul 2026 | MHRA | Updates its borderline-products guidance |
| 18 Nov 2026 | Our check | No UK legislation, no product on the emc and no published MHRA determination naming MOTS-c found |
The two MHRA press releases describe “peptide products” without naming compounds. They show where enforcement has been aimed: unlicensed manufacture and supply, with peptides alongside weight-loss drugs.
04Is MOTS-c a controlled drug in the UK?
No. MOTS-c is not listed in Schedule 2 to the Misuse of Drugs Act 1971, which sets out Classes A, B and C. We read the revised schedule on legislation.gov.uk on 18 November 2026. The peptide hormones that are controlled there, such as somatropin, sit in Class C.
Not being a controlled drug does not settle the medicines question above. The two regimes are separate. The wider picture, including growth hormone and the Psychoactive Substances Act 2016, is on are peptides legal in the UK?
05How is MOTS-c treated in UK sport?
UK sport follows the World Anti-Doping Code. WADA’s Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, among activators of the AMP-activated protein kinase (AMPK). The class is prohibited in and out of competition, and the List says substances in S4.4 are non-Specified Substances, a status that bears on the length of a sanction.
WADA first named MOTS-c in the 2025 List. UK Anti-Doping’s summary of that List gave it as one of the year’s new examples and said: “Please note that these are not new substances being added to the 2025 List for the first time but are additional examples of substances that are already prohibited.” Detail: is MOTS-c banned in sport?
06What changed in 2026?
The law did not change. Enforcement and guidance did.
No new UK law. On 18 November 2026 a legislation.gov.uk full-text search for “MOTS-c”, and phrase searches for “MOTS c” and “mitochondrial open reading frame”, returned no results. The same search for somatropin returned 30.
More enforcement. The MHRA’s Criminal Enforcement Unit announced raids in February and May on premises it believed were used to make and distribute unlicensed weight-loss medicines and peptide products.
Updated guidance. Guidance Note 8 was amended in May and the borderline guidance updated in July.
Outside the UK. The US HHS policy of October 2026, which names MOTS-c, is a draft enforcement policy on compounding by licensed US pharmacies, federal facilities and physicians, and it is not an approval: is MOTS-c legal in the US?
07What we don’t know
How the MHRA would classify a given product. It decides finished products case by case. We found no published MHRA determination naming MOTS-c in its final determinations (to December 2023) or its regulation 165 notices (October 2019 to May 2023).
MHRA Products. We could not run its search. Our check for a licensed UK product is the emc result above.
Northern Ireland. Parts of these rules differ there, and we have not covered them.
The evidence on MOTS-c itself is in our MOTS-c research guide and in MOTS-c claims and the evidence. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.